UCL’s Cancer Immunology group publishes on the relevance of CD25 as a target in cancer

London and Stevenage, UK Tusk Therapeutics, an immuno-oncology company, today announces that its collaborators, Dr. Sergio Quezada and Professor Karl Peggs of the Cancer Immunology group at University College London (UCL), published work in Immunity, a peer-reviewed medical journal, on targeting CD25 with an optimised antibody for the treatment of cancer. The paper entitled, Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T … Read More

Cancer Research Technology, UCL, and Tusk Therapeutics join forces to develop cancer immunotherapies

​London and Stevenage, United Kingdom CANCER RESEARCH TECHNOLOGY, Cancer Research UK’s commercial arm, Tusk Therapeutics, an immuno-oncology company and UCL (University College London) have signed a licence and collaboration agreement to research, develop and commercialise an antibody-based therapeutic against a target that plays a key role in immune suppression in cancer. ​ Under the terms of the agreement, Tusk Therapeutics … Read More